Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
havrix + healive
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This query refers to two separate hepatitis A vaccines that have been compared in clinical studies. **Havrix** is a hepatitis A vaccine manufactured by GlaxoSmithKline (GSK). **Healive** is a Chinese WHO-prequalified inactivated hepatitis A vaccine. Both are inactivated hepatitis A virus vaccines approved for use in persons 12 months of age and older. A comparative study mentioned in the search results indicated that Healive demonstrated stronger protective effects and better antibody persistence than Havrix at 15 years post-vaccination, with prediction indicating at least 30 years of antibody persistence for Healive compared to at least 25 years for Havrix.
Beyond the preview
Go deeper on havrix + healive.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on havrix + healive.